Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy.
暂无分享,去创建一个
C. Boucher | S. Gulnik | J. Erickson | J. Albert | P. Schipper | M. Nijhuis | R. Schuurman | E. Gustchina | J Albert | R Schuurman | M Nijhuis | P Schipper | D de Jong | S Gulnik | J Erickson | E Gustchina | C A Boucher | D. de Jong | John W. Erickson | D. Jong
[1] S. Gulnik,et al. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. , 1995, Biochemistry.
[2] F. Mammano,et al. Loss of Viral Fitness Associated with Multiple Gag and Gag-Pol Processing Defects in Human Immunodeficiency Virus Type 1 Variants Selected for Resistance to Protease Inhibitors In Vivo , 1998, Journal of Virology.
[3] S. Elena,et al. Exponential increases of RNA virus fitness during large population transmissions. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[4] S. J. Clark,et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. , 1993, Science.
[5] A. Perelson,et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.
[6] J. Falloon,et al. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites , 1997, Journal of virology.
[7] W. Keulen,et al. Reduced replication of 3TC‐resistant HIV‐1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. , 1996, The EMBO journal.
[8] E. Domingo,et al. Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy , 1995, Journal of virology.
[9] D. Richman,et al. Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients , 1996, Journal of virology.
[10] C. Boucher,et al. Anti-CD4 therapy for AIDS suggested by mathematical models , 1996, Proceedings of the Royal Society of London. Series B: Biological Sciences.
[11] D. Ho,et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir , 1996, Nature Medicine.
[12] R. Weiss,et al. Recombinant CD4-selected human immunodeficiency virus type 1 variants with reduced gp120 affinity for CD4 and increased cell fusion capacity , 1991, Journal of virology.
[13] S. Elena,et al. Extreme fitness differences in mammalian and insect hosts after continuous replication of vesicular stomatitis virus in sandfly cells , 1995, Journal of virology.
[14] Y. Lin,et al. Proteolytic processing mechanisms of a miniprecursor of the aspartic protease of human immunodeficiency virus type 1. , 1994, Biochemistry.
[15] S. Elena,et al. Basic concepts in RNA virus evolution , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[16] J. Sninsky,et al. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection , 1994, Journal of clinical microbiology.
[17] N. Shen,et al. Extensive polymorphisms observed in HIV–1 clade B protease gene using high–density oligonucleotide arrays , 1996, Nature Medicine.
[18] J. Coffin,et al. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy , 1995, Science.
[19] C. Boucher,et al. Sensitive procedure for the amplification of HIV-1 RNA using a combined reverse-transcription and amplification reaction. , 1995, BioTechniques.
[20] L. M. Mansky,et al. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase , 1995, Journal of virology.
[21] Anthony S. Fauci,et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease , 1993, Nature.
[22] R. Colonno,et al. Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[23] J. Louis,et al. Kinetics and mechanism of autoprocessing of human immunodeficiency virus type 1 protease from an analog of the Gag-Pol polyprotein. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[24] J. Coffin,et al. Genetic diversity and evolution of retroviruses. , 1992, Current topics in microbiology and immunology.
[25] P D Griffiths,et al. Population dynamics of HIV within an individual after treatment with zidovudine , 1991, AIDS.
[26] A. Perelson,et al. HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.
[27] R M Stroud,et al. Domain flexibility in retroviral proteases: structural implications for drug resistant mutations. , 1998, Biochemistry.
[28] J. E. Bouma,et al. Evolution of a bacteria/plasmid association , 1988, Nature.
[29] A S Perelson,et al. Human immunodeficiency virus fitness in vivo: calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase , 1996, Journal of virology.
[30] S. Gulnik,et al. In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine , 1993, Antimicrobial Agents and Chemotherapy.
[31] J. Erickson,et al. Structural mechanisms of HIV drug resistance. , 1996, Annual review of pharmacology and toxicology.
[32] Q. Sattentau,et al. Dissociation of gp120 from HIV-1 virions induced by soluble CD4. , 1990, Science.
[33] D. Lamarre,et al. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors , 1996, Journal of virology.
[34] Ashley T. Haase,et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS , 1993, Nature.
[35] E. Domingo,et al. RNA virus mutations and fitness for survival. , 1997, Annual review of microbiology.
[36] B. Levin,et al. Adaptation to the fitness costs of antibiotic resistance in Escherichia coli , 1997, Proceedings of the Royal Society of London. Series B: Biological Sciences.
[37] R. Lenski,et al. Dynamics of adaptation and diversification: a 10,000-generation experiment with bacterial populations. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[38] R de Boer,et al. Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215 , 1997, Journal of virology.
[39] E. Furfine,et al. Analysis of resistance to human immunodeficiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors , 1995, Journal of virology.
[40] C. Boucher,et al. Replication of a pre-existing resistant HIV-1 subpopulation in vivo after introduction of a strong selective drug pressure. , 1996, Antiviral therapy.
[41] F. Mammano,et al. Resistance-Associated Loss of Viral Fitness in Human Immunodeficiency Virus Type 1: Phenotypic Analysis of Protease andgag Coevolution in Protease Inhibitor-Treated Patients , 1998, Journal of Virology.
[42] J S Sinsheimer,et al. In vivo sequence diversity of the protease of human immunodeficiency virus type 1: presence of protease inhibitor-resistant variants in untreated subjects , 1996, Journal of virology.
[43] M. Salimans,et al. Rapid and simple method for purification of nucleic acids , 1990, Journal of clinical microbiology.
[44] S. Paulous,et al. Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug. , 1996, The Journal of general virology.
[45] D. Ho,et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. , 1995, The New England journal of medicine.
[46] J. Ermolieff,et al. Kinetic properties of saquinavir-resistant mutants of human immunodeficiency virus type 1 protease and their implications in drug resistance in vivo. , 1997, Biochemistry.
[47] C. Boucher,et al. Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[48] L. M. Lehman,et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. , 1995, The New England journal of medicine.
[49] Martin A. Nowak,et al. Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.
[50] R. Siliciano,et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection , 1997, Nature.
[51] John M. Leonard,et al. Genotypic Changes in Human Immunodeficiency Virus Type 1 Associated with Loss of Suppression of Plasma Viral RNA Levels in Subjects Treated with Ritonavir (Norvir) Monotherapy , 1998, Journal of Virology.